

## 2017

1. Beinse, G., Berger, F., Cottu, P., Dujaric, M.-E., Kriegel, I., Guilhaume, M.-N., Diéras, V., Cabel, L., Pierga, J.-Y., and Bidard, F.-C. Circulating tumor cell count and thrombosis in metastatic breast cancer. *J Thromb Haemost.* (2017).
2. Cabel, L., Bidard, F.-C., Servois, V., Cacheux, W., Mariani, P., **Romano, E.**, Minsat, M., Bieche, I., Farkhondeh, F., Jeannot, E., and Buecher, B. HPV circulating tumor DNA to monitor the efficacy of anti-PD-1 therapy in metastatic squamous cell carcinoma of the anal canal: A case report. *Int. J. Cancer.* (2017).
3. Cabel, L., **Proudhon, C.**, Mariani, P., Tzanis, D., Beinse, G., Bieche, I., Pierga, J.-Y., and Bidard, F.-C. Circulating tumor cells and circulating tumor DNA: What surgical oncologists need to know? *Eur J Surg Oncol.* (2017).
4. Cabel, L., Riva, F., Servois, V., Livartowski, A., Daniel, C., Rampanou, A., Lantz, O., **Romano, E.**, **Milder, M.**, Buecher, B., Piperno-Neumann, S., **Bernard, V.**, **Baulande, S.**, Bieche, I., Pierga, J.-Y., **Proudhon, C.**, and Bidard, F.-C. Circulating tumor DNA changes for early monitoring of anti-PD1 immunotherapy: a proof-of-concept study. *Ann Oncol.* (2017).
5. Cabel, Luc, **Proudhon, C.**, Gortais, H., **Loirat, D.**, Coussy, F., Pierga, J.-Y., and Bidard, F.-C. Circulating tumor cells: clinical validity and utility. *Int. J. Clin. Oncol.* (2017).
6. Pierga, J.-Y., Bidard, F.-C., Autret, A., Petit, T., Andre, F., Dalenc, F., Levy, C., Ferrero, J.-M., Romieu, G., Bonnetterre, J., Lerebours, F., Bachelot, T., Kerbrat, P., Campone, M., Eymard, J.-C., Mouret-Reynier, M.-A., Gligorov, J., Hardy-Bessard, A.-C., Lortholary, A., Soulie, P., Boher, J.-M., **Proudhon, C.**, Charafe-Jaufret, E., Lemonnier, J., Bertucci, F., and Viens, P. Circulating tumour cells and pathological complete response: independent prognostic factors in inflammatory breast cancer in a pooled analysis of two multicentre phase II trials (BEVERLY-1 and -2) of neoadjuvant chemotherapy combined with bevacizumab. *Ann. Oncol.* (2017).
7. Riva, F., Bidard, F.-C., Houy, A., Saliou, A., Madic, J., Rampanou, A., **Hego, C.**, **Milder, M.**, Cottu, P., Sablin, M.-P., Vincent-Salomon, A., Lantz, O., Stern, M.-H., **Proudhon, C.**, and Pierga, J.-Y. Patient-Specific Circulating Tumor DNA Detection during Neoadjuvant Chemotherapy in Triple-Negative Breast Cancer. *Clin. Chem.* (2017).

## 2016

1. Bidard, F.-C., **Proudhon, C.**, and Pierga, J.-Y. Circulating tumor cells in breast cancer. *Mol Oncol.* (2016).
2. Bonnefoi, H., Grellety, T., Tredan, O., Saghatchian, M., Dalenc, F., Mailliez, A., L'Haridon, T., Cottu, P., Abadie-Lacourtoisie, S., You, B., Mousseau, M., Dauba, J., Del Piano, F., Desmoulins, I., Coussy, F., Madranges, N., Grenier, J., Bidard, F.-C., **Proudhon, C.**, MacGrogan, G., Orsini, C., Pulido, M., and Gonçalves, A. A phase II trial of abiraterone acetate plus prednisone in patients with triple-negative androgen receptor positive locally advanced or metastatic breast cancer (UCBG 12-1). *Ann. Oncol.* (2016).
3. Ignatiadis, M., Rack, B., Rothé, F., Riethdorf, S., Decraene, C., Bonnefoi, H., Dittrich, C., Messina, C., Beauvois, M., Trapp, E., Goulioti, T., Tryfonidis, K., Pantel, K., Repollet, M., Janni, W., Piccart, M., Sotiriou, C., Litiere, S., and Pierga, J.-Y. Liquid biopsy-based clinical research in early breast cancer: The EORTC 90091-10093 Treat CTC trial. *Eur. J. Cancer.* (2016).
4. Janni, W., Rack, B., Terstappen, L.W., Pierga, J.-Y., Taran, F.-A., Fehm, T., Hall, C., de Groot, M., Bidard, F.-C., Friedl, T.W.P., Fasching, P.A., Brucker, S.Y., Pantel, K.,

## Disseminated disease program

- and Lucci, A. Pooled Analysis of the Prognostic Relevance of Circulating Tumor Cells in Primary Breast Cancer. *Clin. Cancer Res.* (2016).
5. Riva, F., Dronov, O.I., Khomenko, D.I., Huguet, F., Louvet, C., **Mariani, P.**, **Stern, M.-H.**, **Lantz, O.**, **Proudhon, C.**, **Pierga, J.-Y.**, and Bidard, F.-C. Clinical applications of circulating tumor DNA and circulating tumor cells in pancreatic cancer. *Mol Oncol.* (2016).
  6. Saliou, A., Bidard, F.-C., **Lantz, O.**, **Stern, M.-H.**, **Vincent-Salomon, A.**, **Proudhon, C.**, and **Pierga, J.-Y.** Circulating tumor DNA for triple-negative breast cancer diagnosis and treatment decisions. *Expert Rev. Mol. Diagn.* (2016).
  7. Whale, A.S., Devonshire, A.S., Karlin-Neumann, G., Regan, J., Javier, L., Cowen, S., Fernandez-Gonzalez, A., Jones, G.M., Redshaw, N., Beck, J., Berger, A.W., Combaret, V., Kjersgaard, N.D., Davis, L., Fina, F., Forshew, T., Andersen, R.F., Galbiati, S., Hernandez, A.G., Haynes, C., Janku, F., Lacave, R., Lee, J., Mistry, V., Pender, A., Pradines, A., **Proudhon, C.**, Saal, L., Stieglitz, E., Ulrich, B., Foy, C.A., Parkes, H., Tzonev, S., and Huggett, J. An International Inter-Laboratory Digital Pcr Study Demonstrates High Reproducibility for the Measurement of a Rare Sequence Variant. *bioRxiv.* (2016).

## 2015

1. Autebert, J., Coudert, B., Champ, J., Saias, L., Guneri, E.T., **Lebofsky, R.**, Bidard, F.-C., **Pierga, J.-Y.**, Farace, F., Descroix, S., Malaquin, L., and Viovy, J.-L. High purity microfluidic sorting and analysis of circulating tumor cells: towards routine mutation detection. *Lab Chip.* (2015).
2. Bidard, F.-C. Circulating Tumor Cells, a Tremendous Prognostic Factor in Inflammatory Breast Cancer. *J. Natl. Cancer Inst.* (2015).
3. Bidard, F.-C., and **Pierga, J.-Y.** Clinical utility of circulating tumor cells in metastatic breast cancer. *J. Clin. Oncol.* (2015).
4. Bidard, F.-C., Ng, C.K.Y., Cottu, P., Piscuoglio, S., Escalup, L., Sakr, R.A., **Reyal, F.**, **Mariani, P.**, Lim, R., Wang, L., Norton, L., **Servois, V.**, **Sigal, B.**, **Vincent-Salomon, A.**, **Weigelt, B.**, **Pierga, J.-Y.**, and Reis-Filho, J.S. Response to dual HER2 blockade in a patient with HER3-mutant metastatic breast cancer. *Ann. Oncol.* (2015).
5. Helissey, C., Berger, F., Cottu, P., **Diéras, V.**, Mignot, L., **Servois, V.**, Bouleuc, C., Asselain, B., Pelissier, S., Vaucher, I., **Pierga, J.-Y.**, and Bidard, F.C. Circulating tumor cell thresholds and survival scores in advanced metastatic breast cancer: the observational step of the CirCe01 phase III trial. *Cancer Lett.* (2015).
6. **Lebofsky, R.**, Decraene, C., **Bernard, V.**, **Kamal, M.**, Blin, A., Leroy, Q., Rio Frio, T., Pierron, G., Callens, C., Bieche, I., Saliou, A., Madic, J., Rouleau, E., Bidard, F.-C., **Lantz, O.**, **Stern, M.-H.**, **Le Tourneau, C.**, and **Pierga, J.-Y.** Circulating tumor DNA as a non-invasive substitute to metastasis biopsy for tumor genotyping and personalized medicine in a prospective trial across all tumor types. *Molecular Oncology.* (2015).
7. Madic, J., Kialainen, A., Bidard, F.-C., Birzele, F., Ramey, G., Leroy, Q., Rio Frio, T., Vaucher, I., Raynal, V., Bernard, V., Lermine, A., Clausen, I., Giroud, N., Schmucki, R., **Milder, M.**, Horn, C., Spleiss, O., **Lantz, O.**, **Stern, M.-H.**, **Pierga, J.-Y.**, Weisser, M., and Lebofsky, R. Circulating tumor DNA and circulating tumor cells in metastatic triple negative breast cancer patients. *Int. J. Cancer.* (2015).
8. Ng, C.K.Y., Schultheis, A.M., Bidard, F.-C., Weigelt, B., and Reis-Filho, J.S. Breast cancer genomics from microarrays to massively parallel sequencing: paradigms and new insights. *J. Natl. Cancer Inst.* (2015).
9. Perez-Toralla, K., Mottet, G., Guneri, E.T., Champ, J., Bidard, F.-C., **Pierga, J.-Y.**, Klijanienko, J., Draskovic, I., Malaquin, L., Viovy, J.-L., and Descroix, S. FISH in

## Disseminated disease program

chips: turning microfluidic fluorescence in situ hybridization into a quantitative and clinically reliable molecular diagnosis tool. *Lab Chip*. (2015).

10. Pierga, J.-Y., Petit, T., Levy, C., Ferrero, J.M., Campone, M., Gligorov, J., Lerebours, F., Roche, H., Bachelot, T., Charafe-Jauffret, E.A., Bonnetterre, J., Hernandez, J., Bidard, F.-C., and Viens, P. Pathological response and circulating tumor cell count identifies treated HER2+ inflammatory breast cancer patients with excellent prognosis: BEVERLY-2 survival data. *Clin. Cancer Res.* (2015).

## 2014

1. Bidard, F.-C., Madic, J., Mariani, P., Piperno-Neumann, S., Rampanou, A., Servois, V., Cassoux, N., Desjardins, L., **Milder, M.**, Vaucher, I., Pierga, J.-Y., **Lebofsky, R.**, Stern, M.-H., and Lantz, O. Detection rate and prognostic value of circulating tumor cells and circulating tumor DNA in metastatic uveal melanoma: Circulating Tumor DNA in Uveal Melanoma. *Int. J. Cancer*. (2014).
2. Bidard, F.-C., Peeters, D.J., Fehm, T., Nolé, F., Gisbert-Criado, R., Mavroudis, D., Grisanti, S., Generali, D., Garcia-Saenz, J.A., Stebbing, J., Caldas, C., Gazzaniga, P., Manso, L., Zamarchi, R., de Lascoiti, A.F., De Mattos-Arruda, L., Ignatiadis, M., **Lebofsky, R.**, van Laere, S.J., Meier-Stiegen, F., Sandri, M.-T., Vidal-Martinez, J., Politaki, E., Consoli, F., Bottini, A., Diaz-Rubio, E., Krell, J., Dawson, S.-J., Raimondi, C., Rutten, A., Janni, W., Munzone, E., Carañana, V., Agelaki, S., Almici, C., Dirix, L., Solomayer, E.-F., Zorzino, L., Johannes, H., Reis-Filho, J.S., Pantel, K., Pierga, J.-Y., and Michiels, S. Clinical validity of circulating tumour cells in patients with metastatic breast cancer: a pooled analysis of individual patient data. *Lancet Oncol.* (2014).
3. Ignatiadis, M., Riethdorf, S., Bidard, F.-C., Vaucher, I., Khazour, M., Rothé, F., Metallo, J., Rouas, G., Payne, R.E., Coombes, R., Teufel, I., Andergassen, U., Apostolaki, S., Politaki, E., Mavroudis, D., Bessi, S., Pestrin, M., Di Leo, A., Campion, M., Reinholz, M., Perez, E., Piccart, M., Borgen, E., Naume, B., Jimenez, J., Aura, C., Zorzino, L., Cassatella, M., Sandri, M., Mostert, B., Sleijfer, S., Kraan, J., Janni, W., Fehm, T., Rack, B., Terstappen, L., Repollet, M., Pierga, J.-Y., Miller, C., Sotiriou, C., Michiels, S., and Pantel, K. International study on inter-reader variability for circulating tumor cells in breast cancer. *Breast Cancer Res.* (2014).
4. Mottet, G., Perez-Toralla, K., Tulukcuoglu, E., Bidard, F.-C., Pierga, J.-Y., Draskovic, I., Londono-Vallejo, A., Descroix, S., Malaquin, L., and Louis Viovy, J. A three dimensional thermoplastic microfluidic chip for robust cell capture and high resolution imaging. *Biomicrofluidics*. (2014).

## 2013

1. Bidard, F.C., Huguet, F., Louvet, C., Mineur, L., Bouche, O., Chibaudel, B., Artru, P., Desseigne, F., Bachet, J.B., Mathiot, C., Pierga, J.Y., and Hammel, P. Circulating tumor cells in locally advanced pancreatic adenocarcinoma: the ancillary CirCe 07 study to the LAP 07 trial. *Ann. Oncol.* (2013).
2. Bidard, F.-C., Weigelt, B., and Reis-Filho, J.S. Going with the Flow: From Circulating Tumor Cells to DNA. *Science Translational Medicine*. (2013).
3. Bidard, François-Clément, Belin, L., Delaloge, S., Lerebours, F., Ngo, C., **Reyal, F.**, Alran, S., Giacchetti, S., Marty, M., **Lebofsky, R.**, and Pierga, J.-Y. Time-Dependent Prognostic Impact of Circulating Tumor Cells Detection in Non-Metastatic Breast Cancer: 70-Month Analysis of the REMAGUS02 Study. *Int J Breast Cancer*. (2013).
4. Bidard, François-Clément, Fehm, T., Ignatiadis, M., Smerage, J.B., Alix-Panabières, C., Janni, W., Messina, C., Paoletti, C., Müller, V., Hayes, D.F., Piccart, M., and

## Disseminated disease program

- Pierga, J.-Y. Clinical application of circulating tumor cells in breast cancer: overview of the current interventional trials. *Cancer Metastasis Rev.* (2013).
5. Bidard, François-Clément, Pierga, J.-Y., Soria, J.-C., and Thiery, J.P. Translating metastasis-related biomarkers to the clinic—progress and pitfalls. *Nat Rev Clin Oncol.* (2013).
  6. Giordano, A., Egleston, B.L., Hajage, D., Bland, J., Hortobagyi, G.N., Reuben, J.M., Pierga, J.-Y., Cristofanilli, M., and Bidard, F.-C. Establishment and Validation of Circulating Tumor Cell-Based Prognostic Nomograms in First-Line Metastatic Breast Cancer Patients. *Clin. Cancer Res.* (2013).
  7. Ligthart, S. T., Bidard, F.-C., Decraene, C., Bachelot, T., Delaloge, S., Brain, E., Campone, M., Viens, P., Pierga, J.-Y., and Terstappen, L.W.M.M. Unbiased quantitative assessment of Her-2 expression of circulating tumor cells in patients with metastatic and non-metastatic breast cancer. *Ann. Oncol.* (2013).
  8. Ligthart, Sjoerd T., Coumans, F.A.W., Bidard, F.-C., Simkens, L.H.J., Punt, C.J.A., de Groot, M.R., Attard, G., de Bono, J.S., Pierga, J.-Y., and Terstappen, L.W.M.M. Circulating Tumor Cells Count and Morphological Features in Breast, Colorectal and Prostate Cancer. *PLoS ONE.* (2013).
  9. Pierga, J.-Y., Bidard, F.-C., Cropet, C., Tresca, P., Dalenc, F., Romieu, G., Campone, M., Mahier Aït-Oukhtar, C., Le Rhun, E., Gonçalves, A., Leheurteur, M., Dômont, J., Gutierrez, M., Curé, H., Ferrero, J.-M., Labbe-Devilliers, C., and Bachelot, T. Circulating tumor cells and brain metastasis outcome in patients with HER2-positive breast cancer: the LANDSCAPE trial. *Ann. Oncol.* (2013).

## 2012

8. Bidard, F.C., Ferrand, F.R., Huguet, F., Hammel, P., Louvet, C., Malka, D., Boige, V., Ducreux, M., Andre, T., de Gramont, A., Mariani, P., and Pierga, J.-Y. Disseminated and circulating tumor cells in gastrointestinal oncology. *Crit. Rev. Oncol. Hematol.* (2012).
9. Bidard, F.-C., Hajage, D., Bachelot, T., Delaloge, S., Brain, E., Campone, M., Cottu, P., Beuzeboc, P., Rolland, E., Mathiot, C., and Pierga, J.-Y. Assessment of circulating tumor cells and serum markers for progression-free survival prediction in metastatic breast cancer: a prospective observational study. *Breast Cancer Res.* (2012).
10. Campitelli, M., Jeannot, E., Peter, M., Lappartient, E., Saada, S., Rochefordière, A. de la, Fourchette, V., Alran, S., Petrow, P., Cottu, P., Pierga, J.-Y., Lantz, O., Couturier, J., and Sastre-Garau, X. Human Papillomavirus Mutational Insertion: Specific Marker of Circulating Tumor DNA in Cervical Cancer Patients. *PLoS ONE.* (2012).
11. Madic, J., Piperno-Neumann, S., Servois, V., Rampanou, A., **Milder, M.**, Trouiller, B., Gentien, D., Saada, S., Assayag, F., Thuleau, A., Nemati, F., Decaudin, D., Bidard, F.-C., Desjardins, L., Mariani, P., Lantz, O., and Stern, M.-H. Pyrophosphorolysis-Activated Polymerization Detects Circulating Tumor DNA in Metastatic Uveal Melanoma. *Clin. Cancer Res.* (2012).
12. Pierga, J.-Y., Petit, T., Delozier, T., Ferrero, J.-M., Campone, M., Gligorov, J., Lerebours, F., Roché, H., Bachelot, T., Charafe-Jauffret, E., Pavlyuk, M., Kraemer, S., Bidard, F.-C., and Viens, P. Neoadjuvant bevacizumab, trastuzumab, and chemotherapy for primary inflammatory HER2-positive breast cancer (BEVERLY-2): an open-label, single-arm phase 2 study. *Lancet Oncol.* (2012).